NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 6 மணி நேரத்திற்கு முன்இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Entero Q2 FY27 Transcript: Revenue Up 32.9% to ₹2,087 Cr, EBITDA Up 78%, Beats FY27 Guidance
Entero Healthcare Solutions reported a 32.9% YoY increase in Q2 FY27 consolidated revenue to ₹2,087 crore, driven by 18.2% organic growth and 14.7% inorganic expansion from prior acquisitions. Gross margins expanded by 126 bps to 11.5% and EBITDA margin improved by 135 bps to 5.3%, lifting PAT by 66% YoY to ₹61 crore. Management stated that first-half results tracking at ₹4,028 crore (+35% YoY) were ahead of internal expectations and expressed confidence in exceeding their full-year FY27 revenue growth guidance of 23%. Net working capital days stood at 64 days, temporarily impacted by delayed receipt of ₹55 crore in government dues that were subsequently collected in November.
உச்சம் நம்பிக்கை
என்ன மாறியதுSubmission of the formal transcript from the Q2 FY27 earnings conference call held on November 05, 2026.
ஏன் இது முக்கியம்Confirms strong operational momentum with market share gains, margin expansion towards 5.3%, and provides clear management visibility on outperforming FY27 growth targets.
📅 குறுகிய காலம்Cash flow normalization expected in Q3 following the collection of the ₹55 crore delayed government receivable in November.
📈 நீண்ட காலம்Transition toward higher-margin MedTech and value-added healthcare distribution provides structural margin expansion potential beyond traditional low-margin pharma distribution.
⚠ அபாய எச்சரிக்கைகள்
Working capital elongation risk from government and institutional receivables
Integration and pacing of future inorganic acquisitions to maintain growth above 20%
👀 கவனிக்க வேண்டியவை
Track second-half execution towards achieving the targeted 50% EBITDA-to-operating cash flow conversion and monitor margin sustainability in the higher-value MedTech segment.
Entero Subsidiary Faces Rs 11.87 Cr Customer Default; Full Provision Created
Entero Healthcare Solutions announced that its wholly-owned subsidiary, Vasavi Medicare Solutions Private Limited, has experienced a default in payment of outstanding dues totaling INR 11.87 crore from customer M/s. S M Pharma. Due to recoverability risks, Vasavi has fully provided for the entire amount in its books of account, leading to a maximum impact of INR 11.87 crore on consolidated financial statements. The provision represents approximately 7.1% of Entero's TTM net profit of Rs 168 crore and roughly 0.17% of TTM revenue. Vasavi is in the process of initiating legal proceedings to recover the default amount.
உச்சம் நம்பிக்கை
என்ன மாறியதுA key customer (M/s. S M Pharma) defaulted on invoices of INR 11.87 crore to Entero's subsidiary Vasavi, prompting a 100% provision.
ஏன் இது முக்கியம்The full provision will directly ding consolidated net profit by up to INR 11.87 crore, highlighting credit and receivable risks in the distribution chain.
Defaulted amount: INR 11.87 croreProvision amount: INR 11.87 croreImpact vs TTM PAT (Rs 168 Cr): ~7.1%Impact vs TTM Revenue (Rs 7,128 Cr): ~0.17%
📅 குறுகிய காலம்Marginally negative sentiment as quarterly earnings will absorb the INR 11.87 crore provision hit.
📈 நீண்ட காலம்Limited operational impact given the relatively small scale (~0.17% of revenue), though it points to the need for tighter credit terms across subsidiaries.
⚠ அபாய எச்சரிக்கைகள்
Customer credit risk and non-recovery
One-off hit to consolidated quarterly earnings
👀 கவனிக்க வேண்டியவை
Track the upcoming quarterly earnings disclosures to see the timing and P&L impact of the INR 11.87 crore write-off, as well as any progress reported on recovery proceedings.
Entero Healthcare Q2FY27 Revenue Up 33% YoY to ₹2,087 Cr, EBITDA Jumps 78%
Entero Healthcare Solutions reported a 32.9% YoY increase in consolidated revenue to ₹2,087.1 Cr for Q2FY27 (34.7% on like-for-like basis), outpacing IPM growth by ~1.3x. EBITDA rose 78% YoY to ₹110.7 Cr, driven by a 135 bps margin expansion to 5.3%, while consolidated PAT grew 66% YoY to ₹60.7 Cr. Operating cash flow for H1FY27 was negative ₹46.5 Cr due to receivable delays from government contracts, though collections were received in November. Annualized ROCE improved to 22.0% in Q2FY27 from 13.8% in Q2FY26.
உச்சம் நம்பிக்கை
என்ன மாறியதுEntero reported Q2FY27 results showing 33% top-line growth and substantial margin improvement without new acquisitions during the quarter.
ஏன் இது முக்கியம்Demonstrates operating leverage and pricing power via MedTech category expansion, lifting EBITDA margins above 5% and annualised ROCE to 22%.
📅 குறுகிய காலம்Positive earnings momentum supported by strong organic growth (18.2%) running ahead of IPM, though working capital cash burn in H1 requires monitoring.
📈 நீண்ட காலம்Expansion into higher-margin MedTech and diagnostic products provides structural support for gross and EBITDA margin accretion toward 5-6%.
⚠ அபாய எச்சரிக்கைகள்
Negative operating cash flow of ₹46.5 Cr in H1FY27 due to delayed government receivables
High working capital requirements with net operating working capital at 64 days
👀 கவனிக்க வேண்டியவை
Track the normalization of operating cash flows in H2FY27 post-receivable collections and monitor the pace of new MedTech acquisitions.
Entero Healthcare Q2 Standalone PAT Rises to ₹19.14 Cr; Grants 49,712 ESOPs
Entero Healthcare Solutions approved its financial results for Q2 FY27 (quarter ended September 30, 2026). On a standalone basis, revenue from operations reached ₹114.57 crore (up 37.7% YoY from ₹83.22 crore in Q2 FY26) with net profit jumping to ₹19.14 crore from ₹5.70 crore YoY. Standalone basic EPS for the quarter was ₹4.40 compared to ₹1.31 in the year-ago period. Additionally, the company granted 49,712 ESOPs at an exercise price of ₹804 per share under its 2023 Plan.
உச்சம் நம்பிக்கை
என்ன மாறியதுEntero Healthcare declared its standalone Q2 FY27 results showing substantial YoY profit and revenue expansion, alongside granting 49,712 stock options.
ஏன் இது முக்கியம்Demonstrates sustained revenue growth and operational leverage at the parent entity level, supporting the company's broader expansion strategy in pharmaceutical distribution.
📅 குறுகிய காலம்Market may react positively to the strong Standalone PAT surge and top-line growth for the quarter.
📈 நீண்ட காலம்Reflects execution on growth initiatives, though long-term re-rating relies heavily on successful integration of MedTech acquisitions and maintaining consolidated operating margins.
⚠ அபாய எச்சரிக்கைகள்
High working capital requirements across extensive distribution network
Integration risks from acquired subsidiary distribution entities
👀 கவனிக்க வேண்டியவை
Track the full consolidated performance release to assess whether subsidiary MedTech acquisitions are maintaining guided growth and margins relative to the consolidated TTM revenue base of ₹7,128 Cr.
Entero Healthcare Solutions reported a 38.2% YoY revenue growth to ₹1,940 Cr in Q1 FY27, led by 17.8% organic growth and 20.4% inorganic contribution from prior acquisitions. Operating EBITDA surged 94% YoY with margins expanding 143 bps to 5.0%, achieving the management's full-year FY27 margin target in the first quarter itself. PAT increased 72% YoY to ₹52 Cr (PAT attributable to owners stood at ₹38 Cr), aided by scale-led procurement efficiencies and higher-margin MedTech expansion. Management reaffirmed its FY27 guidance of ~23% consolidated revenue growth and expects MedTech revenue to cross ₹1,000 Cr organically.
உச்சம் நம்பிக்கை
என்ன மாறியதுFiling of the official transcript for the Q1 FY27 earnings call outlining detailed operating metrics, margin drivers, and FY27 guidance.
ஏன் இது முக்கியம்Demonstrates operating leverage and working capital optimization across Entero's 138-warehouse network as higher-margin MedTech and retail distribution scale up.
📅 குறுகிய காலம்Positive sentiment supported by healthy top-line expansion, margin achievement, and stable working capital days.
📈 நீண்ட காலம்The company's expansion into higher-margin MedTech products and market share consolidation in pharma distribution support long-term ROCE expansion.
⚠ அபாய எச்சரிக்கைகள்
Significant non-controlling interest (₹14 Cr in Q1) due to partially owned subsidiaries with pending buyout options
Complexity of inventory and working capital management across 138 warehouses
👀 கவனிக்க வேண்டியவை
Track whether the 5% EBITDA margin is sustained through upcoming quarters and monitor organic traction in the higher-margin MedTech segment toward the ₹1,000 Cr milestone.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
38% Revenue Growth and 94% EBITDA Surge in Q1 FY27; ROCE Doubles to 21.1%
Entero Healthcare reported a strong start to FY27 with consolidated revenue reaching Rs 1,940.5 Cr, a 38% YoY increase. Operational efficiency improved significantly as EBITDA grew 94% to Rs 97 Cr, with margins expanding 143 bps to 5.0%. Return ratios showed marked improvement, with ROCE nearly doubling to 21.1% and ROE reaching 20.4%. The company maintained its growth momentum with organic growth of 17.8%, outperforming the Indian Pharmaceutical Market (IPM) growth of 12%.
உச்சம் நம்பிக்கை
என்ன மாறியதுEntero has demonstrated a sharp improvement in profitability and capital efficiency (ROCE/ROE) while maintaining high double-digit organic growth.
ஏன் இது முக்கியம்The results validate the scalability of Entero's distribution model and its successful pivot toward higher-margin MedTech categories, which now command a significant portion of the business.
📅 குறுகிய காலம்Positive sentiment is expected as the company delivers on its growth guidance with substantial margin expansion and improved return ratios.
📈 நீண்ட காலம்The structural shift toward higher-margin MedTech and the consolidation of the fragmented pharma distribution market positions the company for steady long-term growth.
⚠ அபாய எச்சரிக்கைகள்
Integration risks associated with 51+ historical acquisitions
Low operating margins (5%) inherent to the distribution and trading industry
👀 கவனிக்க வேண்டியவை
Monitor the company's ability to sustain 5%+ EBITDA margins and the execution of its MedTech segment, which is targeted to exceed Rs 1,000 Cr in revenue for FY27.
Q1 Standalone PAT Falls 50% YoY to ₹3.46 Cr; Revenue at ₹83.27 Cr
Entero Healthcare reported a weak set of standalone results for Q1 FY27, with net profit dropping 50.3% YoY to ₹3.46 Cr from ₹6.96 Cr. While standalone revenue from operations grew 4.9% YoY to ₹83.27 Cr, profitability was hit by a 120% surge in finance costs (₹5.74 Cr vs ₹2.60 Cr) and a decline in other income. The company continues its strategy of supporting subsidiaries, subscribing to Optionally Convertible Debentures (OCDs) in four entities during the quarter. Board committees were also reconstituted following the retirement of an independent director.
உச்சம் நம்பிக்கை
என்ன மாறியதுEntero reported its Q1 FY27 standalone financials showing margin pressure and announced a transition in its board committee leadership effective August 25, 2026.
ஏன் இது முக்கியம்The sharp rise in standalone finance costs and the drop in standalone PAT suggest increased debt servicing or internal funding costs at the parent level, which warrants monitoring despite the company's aggressive acquisition strategy.
Standalone Revenue (Q1 FY27): ₹83.27 கோடிStandalone PAT (Q1 FY27): ₹3.46 கோடிYoY PAT Growth: -50.3%Finance Costs (Q1 FY27): ₹5.74 கோடிStandalone Revenue vs TTM Cons. Revenue: ~1.7%
📅 குறுகிய காலம்The stock may see negative sentiment in the short term due to the significant drop in standalone profitability and rising interest expenses.
📈 நீண்ட காலம்The long-term outlook depends on the successful integration and margin accretion of the numerous subsidiaries (48+ listed) and the achievement of the 30% revenue growth guidance.
⚠ அபாய எச்சரிக்கைகள்
Sharp increase in finance costs
Significant decline in standalone net profit
High complexity with 48+ subsidiary entities
👀 கவனிக்க வேண்டியவை
Investors should focus on the consolidated financial performance, as standalone revenue represents less than 2% of the group's TTM consolidated revenue, indicating most operations reside in subsidiaries.
Entero Reports FY26 Revenue of ₹6,591 Cr, Up 29.3%; MedTech Target >₹1,000 Cr for FY27
Entero Healthcare has released its FY25-26 Annual Report, reporting a 29.3% revenue growth to ₹6,591 crore, significantly outperforming the broader pharmaceutical market. EBITDA grew 55% YoY to ₹266 crore, with margins expanding from 3.4% to 4.0% due to operating leverage and a better product mix. A key milestone was achieved with positive operating cash flow of ₹96 crore, while ROCE improved to 14.6%. The company is now targeting over ₹1,000 crore in annualized revenue from its MedTech segment in FY27.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has transitioned from a loss-making/low-margin phase to generating positive operating cash flow (₹96 Cr) and significantly higher ROCE (14.6%).
ஏன் இது முக்கியம்The shift toward MedTech and higher-value distribution is improving the margin profile (Gross Margin up 78 bps to 10.3%), which is critical for a low-margin trading business.
📅 குறுகிய காலம்The stock may see positive sentiment as the annual report confirms strong execution on growth and margin expansion targets.
📈 நீண்ட காலம்If Entero successfully scales its MedTech platform to ₹1,000 Cr+, it could structurally re-rate the business from a pure pharma distributor to a high-value healthcare platform.
⚠ அபாய எச்சரிக்கைகள்
Integration risks of multiple acquisitions
High inventory complexity across 136 warehouses
Working capital management in a fragmented market
👀 கவனிக்க வேண்டியவை
Watch for the upcoming AGM on August 19, 2026, and monitor the quarterly progress of the MedTech segment to see if it hits the ₹1,000 crore annualized run rate.
Entero Healthcare FY26 Revenue Jumps 31.5% to ₹6,591 Cr; Targets 5% EBITDA Margin in FY27
Entero Healthcare Solutions reported a robust FY26 with like-for-like revenue growth of 31.5% to ₹6,591 crores, meeting its guidance. EBITDA margins improved to 4% for the full year, driven by procurement efficiencies and a better product mix, while Q4 margins reached 4.5%. The company successfully integrated 7 acquisitions, scaling its MedTech segment to over ₹1,000 crores in annualized revenue. Management has issued a positive outlook for FY27, targeting 23% organic revenue growth and a further margin expansion to 5%.
முக்கிய அம்சங்கள்
FY26 revenue grew 31.5% like-for-like to ₹6,591 crores, outperforming the Indian Pharmaceutical Market (IPM) growth by 1.6x.EBITDA margin expanded by 67 bps YoY to 4% for FY26, with Q4 FY26 EBITDA growing 76% YoY to ₹86 crores.MedTech segment now contributes over ₹1,000 crores in annualized revenue following strategic acquisitions in diagnostics and cardiology.Return on Capital Employed (ROCE) improved significantly to 18.4% in Q4 FY26 from 14.8% in the previous quarter.Management guided for 23% organic revenue growth and 5% EBITDA margins for FY27, with a focus on 50% EBITDA-to-cash conversion.
👀 கவனிக்க வேண்டியவை
Investors should view the consistent margin expansion and successful acquisition integration as a sign of operational maturity. Monitor the normalization of minority interests in FY27, which is expected to drop to 25-27% of PAT from the current 38%.
Entero Healthcare Clarifies INR 114 Mn One-Off Impact and Minority Interest Rise in Q4 FY26
Entero Healthcare Solutions has issued a clarification regarding its Q4 FY26 financial results to address investor concerns over modest profit growth and rising minority interests. The company noted that profit attributable to owners was impacted by one-off items totaling INR 114 million, related to business contract closures and higher provisioning. Furthermore, the increase in non-controlling interest is due to the acquisition of a 51.51% stake in Anand Chemiceutics Private Limited during the quarter. This clarification aims to separate non-recurring costs from the company's core operational performance.
முக்கிய அம்சங்கள்
One-off costs of INR 114 million impacted net profit due to contract closures and provisioning charges.Non-controlling interest rose following the acquisition of a 51.51% stake in Anand Chemiceutics Private Limited.The profit drag originated specifically from standalone financials and wholly owned subsidiaries.Management maintains that the company experienced operational growth during the quarter despite these accounting adjustments.
👀 கவனிக்க வேண்டியவை
Investors should add back the INR 114 million one-off charge to evaluate the company's underlying operational run-rate. Monitor the margin profile of the newly acquired Anand Chemiceutics to see if it remains accretive to the consolidated bottom line.
Entero Healthcare to Host Q4FY26 Earnings Call on May 26, 2026
Entero Healthcare Solutions Limited has scheduled its earnings conference call to discuss the audited financial results for the quarter and full year ended March 31, 2026. The call is set for Tuesday, May 26, 2026, at 12:00 PM IST and will be hosted by DAM Capital Advisors. Top management, including the MD & CEO, COO, and Group CFO, will be present to interact with analysts and institutional investors regarding the company's performance.
முக்கிய அம்சங்கள்
Earnings call scheduled for May 26, 2026, at 12:00 PM IST regarding Q4 and FY26 results.Management participants include MD & CEO Prabhat Agrawal and Group CFO Balakrishnan Natesan Kaushik.The call is hosted by DAM Capital Advisors Ltd with universal access numbers +91 22 6280 1384 and +91 22 7115 8285.International dial-in timings provided for Hong Kong, Singapore, UK, and USA markets.
👀 கவனிக்க வேண்டியவை
Investors should monitor the call for management commentary on revenue growth, margin expansion, and the progress of their inorganic growth strategy in the healthcare distribution sector.
Entero Healthcare's Subsidiary Rada Medisolutions Completes Merger of Two Pharma Distributors
Entero Healthcare Solutions has received regulatory approval for the amalgamation of Chethana Pharma Distributors and CPD Pharma into Rada Medisolutions Private Limited. Both merging entities were wholly-owned subsidiaries of Rada Medisolutions, which is a key part of the Entero group. The merger is effective retrospectively from the Appointed Date of April 15, 2025, following a confirmation order from the Ministry of Corporate Affairs. This internal restructuring is designed to simplify the group's corporate structure and reduce administrative and compliance costs.
முக்கிய அம்சங்கள்
Merger of Chethana Pharma (Paid-up capital ₹30 Lakh) and CPD Pharma (Paid-up capital ₹25 Lakh) into Rada Medisolutions approved.The amalgamation was processed via the Fast-track route under Section 233 of the Companies Act, 2013.The scheme is effective from April 15, 2025, as per the Regional Director's confirmation order dated April 17, 2026.Aims to achieve operational efficiencies and economies of scale by eliminating corporate redundancies in pharmaceutical distribution.Post-merger, the transferee company Rada Medisolutions maintains an authorized share capital of ₹80 Lakh.
👀 கவனிக்க வேண்டியவை
This is a positive internal restructuring that should lead to better margins through cost optimization. Investors should monitor if these efficiencies reflect in the upcoming quarterly consolidated financial statements.
Entero Healthcare Q3 FY26: Revenue Up 26% YoY to ₹1,707 Cr, EBITDA Margins Expand to 4%
Entero Healthcare reported a strong Q3 FY26 with revenue growing 26% YoY to ₹1,707 crores, driven by 17.1% organic growth. EBITDA margins expanded by 30 bps to 4%, while adjusted PAT rose 36% to ₹40 crores after accounting for a one-time labor code impact. The company successfully closed several MedTech acquisitions, projecting this segment's annualized revenue to exceed ₹1,000 crores. Management remains confident in achieving its ₹100 crore operating cash flow target for FY26.
முக்கிய அம்சங்கள்
Revenue grew 26% YoY to ₹1,707 crores with a record 17.1% organic growth rate.EBITDA increased 36% YoY to ₹68 crores, achieving a 4% margin.MedTech acquisitions completed; segment revenue expected to surpass ₹1,000 crores with 50-75 bps EBITDA margin accretion.Net Working Capital improved to 61 days (like-to-like), generating ₹49 crores in operating cash flow this quarter.Adjusted PAT grew 36% YoY to ₹40 crores, excluding a ₹6.1 crore one-off labor code impact.
👀 கவனிக்க வேண்டியவை
Investors should monitor the integration of recent MedTech acquisitions and the company's ability to meet its ₹100 crore operating cash flow guidance in Q4. The shift towards higher-margin MedTech and improved working capital efficiency are positive long-term indicators.
Entero Healthcare Q3 FY26 Revenue at ₹1,067M; PAT Impacted by ₹44.8M Exceptional Item
Entero Healthcare reported a revenue of ₹1,067.35 million for the quarter ended December 31, 2025, showing growth over the previous quarter's ₹832.21 million. Net profit for the quarter stood at ₹8.05 million, significantly impacted by a one-time exceptional charge of ₹44.87 million related to the implementation of New Labour Codes. The company has successfully utilized its total IPO proceeds of ₹5,548 million for debt repayment, working capital, and inorganic growth. Multiple acquisitions were completed during the period, including Ramson Medical and Sri RK Pharma, to strengthen its distribution network.
முக்கிய அம்சங்கள்
Revenue from operations grew to ₹1,067.35 million in Q3 FY26 compared to ₹832.21 million in Q2 FY26.Profit After Tax (PAT) for Q3 FY26 was ₹8.05 million, following a ₹44.87 million exceptional item for labor code compliance.The company fully utilized ₹5,548 million of IPO proceeds, with ₹1,425 million used for debt repayment.Aggressive inorganic expansion continued with the acquisition of six entities including Ramson Medical and Bio-side Technologies.9M FY26 PAT stood at ₹134.59 million on a total income of ₹3,430.76 million.
👀 கவனிக்க வேண்டியவை
Investors should monitor the integration of recent acquisitions and the impact on margins once one-time labor code costs are absorbed. The revenue growth trend is positive, but bottom-line consistency is key for long-term valuation.
Entero Healthcare Q3 Standalone PAT Drops to ₹8.06M; Cancels Two Acquisitions
Entero Healthcare reported a standalone revenue of ₹1,067.36 million for Q3 FY26, showing growth from ₹832.21 million in the previous quarter. However, Standalone Profit After Tax (PAT) plummeted to ₹8.06 million from ₹107.83 million in the same quarter last year, a significant year-on-year decline. This drop was exacerbated by a ₹44.97 million exceptional item related to incremental liabilities from New Labour Codes. Additionally, the company cancelled the proposed acquisitions of Khera Medisolutions and AV Medisolutions due to commercial reasons.
முக்கிய அம்சங்கள்
Standalone Revenue from operations stood at ₹1,067.36 million for Q3 FY26 compared to ₹1,011.52 million YoY.Net Profit (PAT) fell sharply to ₹8.06 million from ₹107.83 million in the corresponding quarter of the previous year.Recognized an exceptional expense of ₹44.97 million (₹33.65 million net of tax) due to New Labour Code compliance.Cancelled two planned acquisitions (Khera Medisolutions and AV Medisolutions) previously announced in 2025.Board approved the grant of 5,000 fresh Employee Stock Options (ESOPs) under the 2023 plan.
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's ability to maintain margins following the sharp decline in profitability and the impact of regulatory labor costs. The cancellation of two acquisitions may signal a more selective approach to inorganic growth or potential valuation hurdles.
Entero Healthcare Q3 Revenue Up 25.6% to ₹1,707 Cr; Achieves Positive Operating Cash Flow
Entero Healthcare reported a strong Q3FY26 with revenue growing 25.6% YoY to ₹1,706.5 crore, driven by 17.1% organic like-for-like growth. The company achieved a significant milestone by generating positive operating cash flow of ₹49 crore during the quarter, reversing previous negative trends. EBITDA margins improved by 29 bps to 4.0%, while adjusted PAT (excluding a one-off labor code impact) rose 36% to ₹40 crore. Management is aggressively expanding into the high-margin MedTech segment, which is projected to exceed ₹1,000 crore in revenue next fiscal year.
முக்கிய அம்சங்கள்
Reported revenue grew 25.6% YoY to ₹1,706.5 Cr, with organic LFL growth outperforming the industry at 17.1%.EBITDA increased by 35.5% YoY to ₹67.8 Cr, with margins expanding to 4.0% from 3.7% YoY.Generated positive Operating Cash Flow of ₹49 Cr in Q3, a sharp turnaround from negative ₹10.3 Cr in Q2FY26.Completed 7 acquisitions year-to-date, with a strategic focus on the MedTech segment to drive margin expansion.Net Working Capital (NWC) days improved to 61 on a like-for-like basis compared to 63 in the previous quarter.
👀 கவனிக்க வேண்டியவை
Investors should take note of the company's successful transition to positive operating cash flow and its margin-accretive acquisition strategy in the MedTech space. The stock remains an attractive growth play as it continues to gain market share and consolidate the fragmented healthcare distribution industry.
Entero Healthcare Completes 51.5% Stake Acquisition in Anand Chemiceutics
Entero Healthcare has successfully closed the acquisition of a 51.5% stake in Anand Chemiceutics, a prominent diagnostic and MedTech solutions provider. This acquisition significantly expands Entero's footprint in the diagnostic distribution space, adding a network of over 1,500 laboratories and hospitals. Management expects the MedTech segment to contribute more than INR 1,000 crore in annualized revenue during the next financial year. This move is a strategic step toward building an integrated healthcare supply chain platform in India.
முக்கிய அம்சங்கள்
Acquired a 51.5% majority stake in Anand Chemiceutics, a diagnostic and MedTech specialist established in 2003.The acquisition adds a customer service network of 1,500+ laboratories, hospitals, and government institutions.MedTech segment is projected to generate over INR 1,000 crore in annualized revenue in the next financial year.Expands capabilities into high-growth areas like advanced genomics and turnkey solutions for hospitals.The deal leverages Entero's proprietary technology platform and distribution reach to scale the acquired business.
👀 கவனிக்க வேண்டியவை
Investors should monitor the integration of Anand Chemiceutics as it provides a significant revenue boost and entry into higher-margin diagnostic segments. The projected INR 1,000 crore revenue contribution makes this a key growth driver for the next fiscal year.
Entero Healthcare Completes Acquisition of 51.51% Stake in Anand Chemiceutics
Entero Healthcare Solutions Limited has successfully completed the acquisition of a 51.51% majority equity stake in Anand Chemiceutics Private Limited. This follows the initial announcement made on November 12, 2025, regarding the proposed transaction. The completion of this acquisition allows Entero to consolidate the financials of Anand Chemiceutics, supporting its inorganic growth strategy. This move strengthens the company's position in the healthcare distribution market.
முக்கிய அம்சங்கள்
Acquired a majority equity stake of 51.51% in Anand Chemiceutics Private Limited.The acquisition process was completed on February 07, 2026.The transaction was previously disclosed on November 12, 2025.The move aligns with SEBI Regulation 30 for material disclosures.
👀 கவனிக்க வேண்டியவை
Investors should monitor the upcoming quarterly results to evaluate the margin profile and revenue contribution of the newly acquired entity.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
